Financial Performance - The company's operating revenue for 2019 was CNY 303,759,977.46, a decrease of 11.77% compared to CNY 344,291,893.87 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 56,966,032.34, down 23.73% from CNY 74,689,446.35 in the previous year[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,479,151.55, a decline of 34.57% from CNY 54,225,894.20 in 2018[16] - The net cash flow from operating activities was CNY 74,087,742.26, which is 11.48% lower than CNY 83,697,141.30 in 2018[16] - Basic earnings per share for 2019 were CNY 0.47, a decrease of 24.19% from CNY 0.62 in the previous year[16] - The overall gross margin for 2019 was 33.26%, a decrease of 1.28 percentage points from the previous year[45] - The total profit and net profit attributable to shareholders were ¥66,006,630.21 and ¥56,966,032.34, representing declines of 24.24% and 23.73% respectively[45] Assets and Liabilities - Total assets at the end of 2019 reached CNY 1,010,052,912.03, an increase of 25.88% compared to CNY 802,418,344.36 at the end of 2018[17] - The net assets attributable to shareholders were CNY 774,434,087.11, reflecting a growth of 4.60% from CNY 740,369,575.05 in 2018[17] - Cash and cash equivalents increased from CNY 68,689,089.35 to CNY 114,313,030.64, a growth of 66.42%, mainly due to increased loans[34] - Other receivables surged from CNY 1,467,743.89 to CNY 40,421,274.76, a staggering increase of 2653.97%, attributed to land compensation and export tax rebates[35] - Long-term borrowings reached ¥77,000,000.00, accounting for 7.62% of total assets, primarily due to loans for the cogeneration project[76] Revenue Sources - The revenue from veterinary medicine accounted for 88.53% of total revenue, amounting to ¥268.93 million, down 13.56% from ¥311.12 million in 2018[57] - Domestic sales revenue increased by 16.52% as the company adjusted its product structure in response to regulatory changes[45] - Export revenue declined by 23.69% due to significant changes in the procurement plans of major client, M.S. Technologies[45] Research and Development - The company has obtained a total of 10 invention patents and 15 utility model patents by the end of 2019, showcasing its strong R&D capabilities[37] - The company plans to enhance its product structure by developing "safe, efficient, low/no residue, and poultry-specific" veterinary raw materials and formulations[46] - Research and development expenses increased by 27.35% to ¥18,549,953.82, representing 6.11% of the company's total revenue[69] Investments and Expansion - The company invested ¥4,600 million in a pharmaceutical industry fund to target high-growth health projects[48] - The company established a joint venture, Fujian Green Home Biotechnology Co., Ltd., with an investment of ¥5.1 million, focusing on nutritional feed additives[47] - The company’s construction projects include a production capacity of 1,200 tons of active bacterial peptide premix and veterinary raw materials, indicating significant market expansion efforts[34] Risk Factors - The company has identified potential risks in its future development outlook, which investors should be aware of[5] - The company faces risks including major customer dependency, with significant fluctuations in procurement plans from key client, Masterton[107] - Environmental regulations pose a risk as the veterinary drug industry is classified as a heavily polluting sector[107] Corporate Governance - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, with strict adherence to this commitment[119] - Major shareholders are restricted from reducing their holdings for two years after the lock-up period, with a maximum annual reduction of 25% of their total shares[120] - The company has established a voluntary lock-up period for its shares, ensuring stability in the market post-IPO[120] Social Responsibility - The company provided assistance to 17 impoverished families through its "Love Fund" in 2019, donating a total of 34,400 yuan[162] - The company donated 100,000 yuan to the Nanping Charity Association in 2019[162] - The company plans to continue its "New Rural Construction" poverty alleviation program, actively engaging in local government initiatives[165] Environmental Compliance - The company has established a wastewater treatment workshop to handle wastewater, ensuring compliance with urban sewage treatment standards[168] - The company received approval for its environmental impact report for the cogeneration project in September 2019[169] - The company has two emission outlets for nitrogen oxides, with a total emission of 43.9 tons per year, which is below the regulatory limit[167]

Financial Performance - Operating income decreased by 10.21% to ¥76,861,147.27 for the current period, and by 13.07% to ¥220,485,654.60 year-to-date[8] - Net profit attributable to shareholders decreased by 46.39% to ¥9,839,666.26 for the current period, and by 40.88% to ¥35,280,914.77 year-to-date[8] - Basic earnings per share decreased by 46.67% to ¥0.08 for the current period, and by 42.00% to ¥0.29 year-to-date[8] - Net profit decreased by 40.50% to ¥35.51 million, primarily due to a reduction in operating income[17] - The company reported a significant increase in revenue for Q3 2019, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[22] - The net profit for Q3 2019 was CNY 35,512,662.08, down from CNY 59,680,819.50 in the same period last year, representing a decline of approximately 40.4%[58] - The total operating revenue for the year-to-date period was CNY 220,485,654.60, down 13% from CNY 253,647,847.03 in the previous year[55] Assets and Liabilities - Total assets increased by 11.48% to ¥894,558,304.56 compared to the end of the previous year[8] - Cash and cash equivalents increased by 79.85% to ¥123.53 million due to new technical transformation loans of ¥50 million[16] - Inventory decreased by 35.76% to ¥30.17 million, attributed to a reduction in finished goods and semi-finished products[16] - The company has short-term borrowings of CNY 35,000,000.00, indicating reliance on debt financing[39] - Total liabilities increased significantly to CNY 140,219,487.62 from CNY 57,136,038.36, indicating a rise in financial obligations[45] - Total equity reached ¥737,344,703.61, including retained earnings of ¥197,656,792.29[80] Cash Flow - Net cash flow from operating activities increased by 79.89% to ¥35,642,822.44 for the current period[8] - The cash flow from operating activities was CNY 237,942,382.74, down from CNY 259,458,422.75 in the previous period[64] - The net cash flow from operating activities for Q3 2019 was CNY 64,912,417.97, an increase from CNY 58,237,321.67 in Q3 2018, reflecting a growth of approximately 11.5%[65] - The total cash inflow from investment activities was CNY 405,912,933.69, compared to CNY 510,560,206.24 in the previous year, indicating a decrease of about 20.5%[66] Research and Development - Research and development expenses rose by 43.50% to ¥14.73 million, reflecting increased investment in R&D[17] - Research and development expenses increased to CNY 14,511,371.52 from CNY 10,262,697.08, indicating a focus on innovation[61] - The company plans to invest $10 million in R&D for new technologies aimed at improving product efficacy[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,072[12] - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.32% of shares, amounting to 36,378,000 shares[12] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[13] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2020[20] - A strategic acquisition of a local competitor was completed, which is anticipated to enhance the company's production capacity by 30%[21] - The management emphasized a commitment to sustainability, aiming for a 25% reduction in carbon footprint by 2025[21] Compliance and Governance - The management reiterated its commitment to transparency and compliance with regulatory requirements regarding related party transactions[23] - The company confirmed that there were no non-operational fund occupations by controlling shareholders or their affiliates[28] - The company has committed to not transferring benefits to other entities or individuals unfairly[27]

Financial Performance - The company's operating revenue for the first half of 2019 was ¥143,624,507.33, a decrease of 14.53% compared to ¥168,046,128.52 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was ¥25,441,248.51, down 38.44% from ¥41,328,343.81 in the previous year[16]. - The net profit after deducting non-recurring gains and losses was ¥16,269,514.37, a decline of 43.92% compared to ¥29,013,682.40 in the same period last year[16]. - The net cash flow from operating activities was ¥29,269,595.53, which is 23.82% lower than ¥38,423,513.34 in the previous year[16]. - The basic earnings per share decreased to ¥0.21, down 38.24% from ¥0.34 in the same period last year[16]. - The overall gross margin for the first half of 2019 was 30.67%, a decrease of 4.78 percentage points compared to the previous year[42]. - The company reported a significant increase in feed additive revenue, which rose by 351.45% to ¥1,135,492.54[56]. - The company reported a total profit of ¥29,309,342.78, down from ¥48,901,487.59 year-on-year[165]. - Total comprehensive income for the first half of 2019 was ¥24,628,708.94, compared to ¥38,270,288.25 in the same period of 2018, representing a decrease of approximately 35.5%[171]. Assets and Liabilities - Total assets at the end of the reporting period were ¥817,858,358.86, an increase of 1.92% from ¥802,418,344.36 at the end of the previous year[16]. - The company's total equity was ¥731,973,412.55, slightly down from ¥737,344,703.61[165]. - Total liabilities increased to ¥81,398,783.08 from ¥62,048,769.31, marking an increase of approximately 31.1%[157]. - The company's equity attributable to shareholders decreased to ¥735,780,822.56 from ¥740,369,575.05, a decline of about 0.6%[157]. - The company's cash and cash equivalents increased to ¥68,685,799.03, representing 8.40% of total assets, up from 6.14% in the previous year[60]. Investments and R&D - Research and development investment increased by 34.14% to ¥8.15 million, reflecting the company's commitment to enhancing R&D efforts[54]. - The company plans to enhance its market share in the bacteriophage peptide product line and develop new green and healthy veterinary products[43]. - The company has committed a total investment of ¥36,815.23 million for various projects, with a cumulative investment of ¥5,872.44 million as of the reporting period[79]. - The company has invested approximately ¥20.12 million in a cogeneration project to ensure stable heating quality and reduce electricity costs, which will support future business expansion[51]. Market and Industry Trends - The global population is projected to reach 8 billion by 2025, driving demand for meat, egg, and dairy products, which benefits the livestock and feed industries[28]. - The veterinary drug market is shifting towards products that are efficient, low-residue, and low-toxicity, driven by increasing food safety concerns and regulatory pressures[28]. - The company faces risks from changes in industry policies, particularly regarding the use of drug feed additives, which may impact future product usage and demand[90]. - The African swine fever outbreak has led to a significant decline in pig inventory, with a year-on-year decrease of 25.8% by June 2019, potentially affecting the veterinary medicine market[91]. Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, indicating a focus on reinvestment[96]. - The company will vote in favor of share repurchase plans approved by the shareholders' meeting to stabilize the stock price[101]. - The company has made commitments to fulfill measures related to compensation for diluted immediate returns, ensuring compliance with regulatory requirements[101]. - The company has established a plan to stabilize its stock price within three years of listing, which includes specific obligations for major shareholders[100]. Social Responsibility and Environmental Compliance - The company has established a "Love Fund" to support impoverished families, donating a total of ¥34,400 to 17 families in early 2019[126]. - The company has installed online monitoring systems for both wastewater and air emissions, ensuring compliance with environmental regulations[121]. - The company has been recognized for its efforts in poverty alleviation, with a total investment of ¥884,000 in various initiatives[127]. Operational Risks - The company faces various operational risks, which are detailed in the report[6]. - Currency fluctuations, particularly the RMB to USD exchange rate, could impact the company's financial performance due to international sales[92]. - The company is at risk of losing key talent due to competitive pressures in the industry, which could hinder long-term growth prospects[92].

证券代码：002868 证券简称：绿康生化 公告编号：2019-050 绿康生化股份有限公司 关于参加 2019 年福建辖区上市公司投资者集体 接待日活动的公告 | --- | |-------------------------------------------------------------------------------------------------| | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 | | | | 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 | | 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 2019 年 7 月 18 | | 日下午 14:00-17:00 参加由福建证监局协同深圳市全景网络有限公司组织开展 | | 2019 年福建辖区上市公司投资者集体接待日活动。现将有关事项公告如下： | | 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 | | 络 远 程 的 方 式 举 行 ， 投 资 者 可 以 登 录 " 全 景 · 路 演 天 下 " 网 站 ...

Financial Performance - The company's revenue for Q1 2019 was ¥67,835,010.75, a decrease of 24.07% compared to ¥89,333,016.72 in the same period last year[7] - Net profit attributable to shareholders was ¥10,768,027.84, down 41.98% from ¥18,560,694.94 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥9,153,663.93, a decline of 39.05% compared to ¥15,019,533.71 in the previous year[7] - Basic and diluted earnings per share were both ¥0.09, a decrease of 40.00% from ¥0.15 in the previous year[7] - Total profit for Q1 2019 was $11.04 million, reflecting a decline of 49.99% from $22.08 million in Q1 2018, attributed to decreased operating profit[15] - The total comprehensive income for the first quarter was CNY 10,829,978.87, compared to CNY 16,848,172.80 in the previous year, reflecting a decrease of approximately 35.9%[46] Cash Flow and Assets - The net cash flow from operating activities was ¥12,047,245.50, down 36.26% from ¥18,901,523.19 in the same period last year[7] - Cash received from other operating activities was $1.96 million in Q1 2019, a decrease of 44.91% from $3.55 million in Q1 2018, mainly due to reduced government subsidies[16] - Cash recovered from investments was $67.50 million in Q1 2019, down 59.57% from $166.96 million in Q1 2018, due to decreased recovery of principal and returns from financial products[17] - Cash paid for fixed assets and other long-term assets was $17.63 million in Q1 2019, a decrease of 37.06% from $28.02 million in Q1 2018, related to payments for expansion projects[17] - Total assets at the end of the reporting period were ¥798,881,044.77, a slight decrease of 0.44% from ¥802,418,344.36 at the end of the previous year[7] - Cash and cash equivalents decreased to CNY 52,534,805.92 from CNY 68,689,089.35, representing a decline of about 23.5%[30] Liabilities and Equity - Total liabilities decreased to CNY 47,743,441.88 from CNY 62,048,769.31, a reduction of approximately 23%[32] - The company's equity increased to CNY 751,137,602.89 from CNY 740,369,575.05, an increase of about 1.04%[33] - Short-term borrowings increased to ¥5,000,000.00, marking a 100% rise as the company took on new bank loans[14] - Total liabilities decreased to CNY 44,311,060.05 from CNY 57,136,038.36 year-over-year, a reduction of 22.5%[38] Operational Changes and Strategies - Management expenses increased by 35.66% to $2.99 million in Q1 2019, primarily due to adjustments in employee compensation related to social insurance contributions[15] - The company is expanding its market presence, targeting an increase in market share by 10% in the next year through strategic partnerships and marketing initiatives[20] - Research and development investments have increased by 30% in Q1 2019, focusing on innovative technologies to enhance product offerings[20] - A new marketing strategy has been implemented, aiming to increase brand awareness by 40% over the next six months[20] Shareholder Commitments - The management emphasized the importance of maintaining shareholder value, with a commitment to return at least 50% of net profits through dividends and share buybacks[20] - The company has committed to stabilizing its stock price for three years post-IPO, with a plan to repurchase shares if the stock price falls below the audited net asset value per share for 20 consecutive trading days[21] - The company has promised to fulfill obligations related to the share repurchase plan approved by the shareholders' meeting, ensuring compliance with regulatory requirements[22] - The company has established measures to prevent the dilution of shareholder interests and committed to not interfering with the company's management or misappropriating company benefits[22] Future Outlook - The company provided guidance for the upcoming quarter, projecting a revenue growth of 20% to 30%, aiming for a total revenue between 1.8 billion and 2 billion RMB[20] - New product launches are expected to contribute significantly to revenue, with three new products scheduled for release in Q2 2019, anticipated to generate an additional 500 million RMB[20] - The company is exploring potential acquisitions to bolster its product line, with a budget of 200 million RMB allocated for this purpose in 2019[20]

Financial Performance - The company's operating revenue for 2018 was CNY 344,291,893.87, a decrease of 8.29% compared to CNY 375,411,280.69 in 2017[16] - The net profit attributable to shareholders for 2018 was CNY 74,689,446.35, down 13.08% from CNY 85,924,989.08 in the previous year[16] - The net profit after deducting non-recurring gains and losses was CNY 54,225,894.20, reflecting a significant decline of 30.92% compared to CNY 78,491,721.13 in 2017[16] - The net cash flow from operating activities was CNY 83,697,141.30, a decrease of 12.91% from CNY 96,109,559.05 in the prior year[16] - The basic earnings per share for 2018 was CNY 0.62, down 20.51% from CNY 0.78 in 2017[16] - The overall gross profit margin for 2018 was 34.54%, a decrease of 5.91 percentage points compared to the previous year[42] - Domestic sales revenue fell by approximately 14.96% year-on-year, influenced by the African swine fever epidemic[42] Assets and Equity - The total assets at the end of 2018 were CNY 802,418,344.36, an increase of 6.11% from CNY 756,245,017.73 at the end of 2017[17] - The net assets attributable to shareholders at the end of 2018 were CNY 740,369,575.05, up 6.42% from CNY 695,680,128.70 at the end of 2017[17] - The company's equity assets increased from 0.00 to ¥45,661,040.96, a growth of 100% due to investments in Huaxing Kangping Pharmaceutical Industry (Pingtan) Investment Management Co., Ltd.[33] - Intangible assets rose from ¥13,739,291.44 to ¥33,646,639.14, marking a 144.89% increase primarily from the acquisition of land use rights and heating projects[33][34] Cash Flow and Investments - The net cash flow from investment activities was -¥55,951,380.85, an improvement of 83.68% compared to the previous year[67] - Financing cash inflow plummeted by 99.86% to ¥547,948.64, mainly due to the absence of funds from the initial public offering received in the previous year[68] - The company has invested CNY 30 million in structured deposits linked to SHIBOR as part of its cash management strategy[76] - The total amount of structured deposits held by the company is CNY 305 million, with a total interest income of CNY 8.56 million[76] Market and Product Development - The main products include Bacillus peptide products, which are used as feed additives to promote livestock growth and prevent intestinal diseases[27] - The company is one of the few that has received FDA on-site approval for its methylene salicylic acid Bacillus peptide products, enhancing its market credibility[27] - The global demand for veterinary drugs is shifting towards lower residue and toxicity, driven by increasing food safety concerns[30] - The company plans to invest approximately ¥201.17 million in a cogeneration project to enhance energy efficiency and reduce costs[48] Risk Factors - The company has identified potential risks in its future development, which are detailed in the report[7] - The company faces risks from policy changes regarding drug feed additives, which may create uncertainty in downstream demand starting July 2020[93] - The company is exposed to raw material price fluctuations, particularly for key inputs like soybean meal and corn starch, which can impact production costs[94] Shareholder and Governance - The company plans to actively utilize capital market financing and pursue mergers and acquisitions to enhance its competitiveness in the pharmaceutical health sector[92] - The company reported a strict commitment to not transfer or manage shares directly or indirectly held for 36 months post-IPO, with a reduction limit of 25% in the following two years[104] - Major shareholders have committed to not transferring shares for 12 months post-IPO, with a similar 25% reduction limit thereafter[105] - The company has maintained compliance with all commitments made during its IPO process[104] Social Responsibility and Environmental Management - The company is committed to fulfilling its social responsibilities, including supporting local poverty alleviation efforts and employee welfare[134] - The company has a pollution discharge management system in place, with chemical oxygen demand emissions at 58.73 mg/L, well below the standard of 120 mg/L[139] - The company has established a charity fund that helped 18 impoverished families with a total donation of 135,500 yuan in 2018[135] Employee and Management Structure - The total number of employees in the company is 526, with 498 in the parent company and 28 in major subsidiaries[174] - The company has a strong management team with the chairman and general manager, Mr. Lai Tanping, receiving 94.8 million yuan in remuneration[173] - The management team has undergone changes, with four new independent directors appointed to enhance governance and oversight[161] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue increase of 20% to 1.44 billion RMB[162] - New product development is underway, with two new product lines expected to launch in Q3 2019, aiming to capture a larger market share[162] - The company aims to expand its domestic and international market presence by increasing sales and marketing efforts[90]

Financial Performance - Net profit attributable to shareholders was ¥18,352,475.69, a decrease of 26.37% year-on-year[9]. - Operating revenue for the period was ¥85,601,718.51, down 16.30% compared to the same period last year[9]. - Basic earnings per share were ¥0.15, a decrease of 28.57% year-on-year[9]. - The weighted average return on equity was 2.56%, down 1.17 percentage points from the previous year[9]. - Net profit for the first nine months of 2018 was ¥59,680,819.50, a decrease of 16.74% compared to the same period in 2017[17]. - The company expects a net profit for 2018 to decrease by 15.00% to 0.00%, influenced mainly by rising raw material prices[21]. Cash Flow and Assets - The net cash flow from operating activities was ¥19,813,808.33, reflecting a significant decline of 51.72%[9]. - Cash and cash equivalents decreased by 49.09% to ¥36,519,423.19 due to dividend distribution and investment in financial products[17]. - Accounts receivable decreased by 71.57% to ¥694,500.00 primarily due to a reduction in bank acceptance bills received[17]. - Prepayments increased by 515.14% to ¥3,154,911.51 due to increased reserves of soybean meal and related raw materials[17]. - Total assets at the end of the reporting period reached ¥774,656,000.44, an increase of 2.43% compared to the end of the previous year[9]. Shareholder Information - The total number of shareholders at the end of the reporting period was 14,779[13]. - The top shareholder, Shanghai Kangyi Investment Co., Ltd., held 30.32% of the shares, amounting to 36,378,000 shares[13]. - The company did not engage in any repurchase transactions during the reporting period[14]. Investments and Expenditures - Investment income surged by 66,522.10% to ¥10,897,623.95, driven by increased income from fundraising and self-owned financial products[17]. - Investment payments increased by 61.46% to ¥532,808,000.00, primarily due to increased purchases of financial products and investments in industrial funds[18]. - The company constructed a technology center, resulting in capital expenditures of ¥38,544,580.05, an increase of 187.07%[18]. Future Outlook and Strategy - The company provided a positive outlook for Q4 2018, expecting continued growth in revenue and user engagement[26]. - Future guidance suggests a revenue growth target of 30% for the next fiscal year[26]. - The company aims to invest in research and development to innovate new technologies and products[26]. - Strategic acquisitions are being considered to bolster the company's market position and technological capabilities[26]. - The company is exploring market expansion opportunities in new regions to increase its customer base[26]. - The company is implementing new strategies to improve operational efficiency and reduce costs[26]. - Overall, the company remains optimistic about its growth trajectory and market opportunities[26]. Miscellaneous - The company reported non-recurring gains and losses totaling ¥14,310,376.45 for the year-to-date period[11]. - Cash received from operating activities related to government subsidies increased by 45.55% to ¥7,067,034.81[18]. - The company did not experience any expected impairment of principal in entrusted financial management during the reporting period[28]. - There were no research, communication, or interview activities conducted by the company during the reporting period[28]. - The company’s chairman, Lai Tanping, provided insights on the financial performance during the earnings call[29].

Financial Performance - The company's operating revenue for the first half of 2018 was ¥168,046,128.52, a decrease of 9.78% compared to ¥186,264,618.64 in the same period last year[18]. - The net profit attributable to shareholders was ¥41,328,343.81, down 11.61% from ¥46,756,439.22 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥29,013,682.40, a significant decline of 34.85% compared to ¥44,535,483.51 in the previous year[18]. - The basic earnings per share decreased by 30.61% to ¥0.34 from ¥0.49 in the same period last year[18]. - The overall gross profit margin for the first half of 2018 was 35.45%, a decrease of 7.52 percentage points compared to the previous year[45]. - Domestic sales revenue declined by approximately 13.01% due to unfavorable conditions in the pig farming industry, including low prices and reduced stock numbers[45]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2018, representing a year-on-year growth of 25%[94]. - The company provided a positive outlook for the second half of 2018, projecting a revenue growth of 20% to 30% based on current market trends and user acquisition strategies[94]. Assets and Liabilities - Total assets at the end of the reporting period were ¥757,780,734.72, a slight increase of 0.20% from ¥756,245,017.73 at the end of the previous year[18]. - The net assets attributable to shareholders increased by 1.63% to ¥707,008,472.51 from ¥695,680,128.70 at the end of the previous year[18]. - The company’s long-term equity investments increased from CNY 0 to CNY 46,000,000.00 during the reporting period, mainly due to participation in an industrial fund[35]. - The total liabilities decreased to CNY 50,772,262.21 from CNY 60,564,889.03, a reduction of approximately 16.0%[159]. - The total owner's equity at the end of the period was 656.5 million yuan, compared to 707.0 million yuan in the previous period[182]. Cash Flow - The net cash flow from operating activities was ¥38,423,513.34, down 7.91% from ¥41,723,226.05 in the previous year[55]. - The company reported a significant increase of 89.14% in net cash flow from investing activities, recovering from a loss of ¥308,049,264.01 to a loss of ¥33,448,223.53[55]. - The cash flow from financing activities included CNY 30,015,565.61 paid in dividends and interest, compared to CNY 30,301,007.92 in the previous period[171]. Investments and Projects - The company has committed to an investment project for a 2,400 tons/year active bacterial peptide series product expansion, which has not yet been completed and has not generated any benefits[74]. - The company has established a wholly-owned subsidiary, Green Kang (Pingtan) Investment Co., Ltd., to engage in capital operations and resource integration in the health industry[47]. - The investment fund initiated by Green Kang Pingtan has raised CNY 46 million to focus on high-growth health projects, with a completed investment of CNY 25 million in Toxin Biotechnology Co., Ltd., acquiring 25% equity[47]. Market Position and Strategy - The company exports approximately 70% of its products, positioning itself as a leading manufacturer in the global market for similar products[34]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% market share in the region by the end of 2019[94]. - A strategic acquisition is planned, with the company in discussions to acquire a competitor, which could potentially increase market share by 10%[95]. - The company is actively pursuing potential mergers and acquisitions to strengthen its market position[99]. Research and Development - The company emphasizes continuous technological innovation to maintain a leading position in product quality and production processes[38]. - The company is investing in new technology, allocating 100 million RMB towards R&D to enhance product efficiency and sustainability[94]. - New product development is underway, with the launch of two innovative products expected by Q4 2018, aimed at expanding the product line and enhancing market competitiveness[95]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[117]. - The company reported a total wastewater discharge of 15.6 tons per year, with a chemical oxygen demand (COD) level of 70.2 mg/L, which is below the regulatory limit of 120 mg/L[118]. - The company contributed a total of 135,500 RMB to assist 18 impoverished families through its charity fund in early 2018[125]. - The company supported rural construction initiatives in two villages, providing 10,000 RMB each for development projects[125]. Shareholder Information - The company has a total of 120 million shares outstanding, with 81.54 million shares subject to restrictions, representing 67.95% of total shares[133]. - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.32% of the shares, totaling 36,378,000 shares[137]. - The company has committed to a share repurchase plan approved by the shareholders' meeting to stabilize stock prices[97]. Compliance and Governance - The company has made commitments to ensure compliance with regulatory requirements and to avoid any actions that could harm shareholder interests[98]. - The company has not sold any significant assets or equity during the reporting period[79]. - The financial statements accurately reflect the company's financial position, operating results, and cash flows in accordance with accounting standards[195].

Financial Performance - Revenue for Q1 2018 was ¥89,333,016.72, a decrease of 8.04% compared to ¥97,143,539.02 in the same period last year[7] - Net profit attributable to shareholders was ¥18,560,694.94, down 30.00% from ¥26,516,196.74 year-on-year[7] - Basic earnings per share decreased by 48.28% to ¥0.15 from ¥0.29 in the previous year[7] - The weighted average return on equity fell to 2.63%, down 6.69% from 9.32% in the same period last year[7] - Operating revenue for Q1 2018 was 89,333,016.72, a decrease of 8.04% compared to Q1 2017's 97,143,539.02[17] - Net profit for Q1 2018 was 18,560,694.94, down 30.00% from 26,516,196.74 in Q1 2017[17] - The company reported a significant increase in foreign exchange losses impacting net profit[17] - The net profit attributable to shareholders for the first half of 2018 is expected to range from 37.41 million to 46.76 million RMB, reflecting a decrease of 20.00% to an increase of 0.00% compared to the same period in 2017[25] Assets and Liabilities - Total assets increased by 0.75% to ¥761,923,599.04 compared to ¥756,245,017.73 at the end of the previous year[7] - Net assets attributable to shareholders rose by 2.67% to ¥714,240,823.64 from ¥695,680,128.70 at the end of last year[7] - Cash paid for fixed assets and other long-term assets increased by 322.06% to 28,015,594.78 from 6,637,765.00 in the previous year[18] - Cash used for investment payments was 168,068,000.00, with no prior year comparison[18] Government Support and Subsidies - The company received government subsidies amounting to ¥3,533,950.62 during the reporting period[8] - Other income for the year included government subsidies amounting to 3,533,950.62, following a change in accounting policy[17] Operational Changes and Investments - Prepayments increased significantly by 173.41% to ¥1,402,244.25, mainly due to increased raw material purchases[16] - Construction in progress rose by 43.90% to ¥7,087,997.29, primarily for the expansion of the technology center[16] - Other non-current assets surged by 1,019.97% to ¥2,025,467.65, reflecting prepayments for the construction of a research and development center[16] - The company experienced an increase in operating costs by 6.49% to 58,711,274.17 due to rising raw material prices[17] - The company is investing in R&D, allocating 15% of its revenue towards the development of new technologies[22] Market and Growth Outlook - User data showed an increase in active users by 25% compared to the previous quarter, reaching a total of 1.5 million active users[22] - The company provided a positive outlook for the upcoming quarters, projecting a revenue growth of 20% for the next quarter[22] - New product launches are expected to contribute an additional $5 million in revenue by the end of Q2 2018[22] - Market expansion plans include entering two new international markets by the end of 2018, targeting a 10% increase in market share[22] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $10 million allocated for potential acquisitions[22] Compliance and Governance - The management emphasized the importance of maintaining compliance with regulatory requirements in all business operations[22] - The company has committed to avoiding any conflicts of interest in its operations and transactions with related parties[22] - The company has committed to not interfere with operational management and to uphold the interests of the company[24] - There are no reported violations regarding external guarantees during the reporting period[27] - The company reported no non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[28] - The company maintains a focus on operational integrity and compliance with financial regulations[28] Investor Relations - The company conducted an on-site investigation on March 8, 2018, with institutional investors participating[29] - The company disclosed investor relations activities on March 9, 2018, on the Giant Tide information website[29] - The chairman of the company is Lai Tanping, who is actively involved in investor communications[29] - The company is committed to transparency in its financial reporting and investor relations activities[29] - The company continues to engage with investors to enhance understanding of its business operations[29] - The company is open to future discussions and communications with stakeholders to foster relationships[29] Shareholder Actions - The company did not distribute dividends or pay interest during the period, reflecting a decrease in bank loans[18] - The company plans to implement a share repurchase plan to stabilize stock prices as approved by the shareholders' meeting[24] - A share buyback plan is in place if the stock price falls below the audited net asset value per share within three years post-IPO[22] - The company’s major shareholders have pledged to support the share repurchase plan to stabilize stock prices[24]

Financial Performance - The company's operating revenue for 2017 was CNY 375,411,280.69, a decrease of 6.50% compared to 2016[16] - The net profit attributable to shareholders for 2017 was CNY 85,924,989.08, down 6.97% from the previous year[16] - The net cash flow from operating activities decreased by 29.02% to CNY 96,109,559.05 in 2017[16] - Basic earnings per share for 2017 were CNY 0.78, a decline of 24.27% compared to 2016[16] - The total revenue for 2017 was CNY 375,411,280.69, a decrease of 6.50% compared to the previous year, primarily due to regulatory changes affecting product classifications and a decline in export prices due to currency fluctuations[47] - The net profit attributable to shareholders for 2017 was CNY 85,924,989.08, down 6.97% year-on-year, influenced by the decrease in revenue and increased financial expenses from exchange losses[47] - The gross profit margin for the year was 40.44%, an increase of 1.21 percentage points compared to the previous year, reflecting improved production efficiency and raw material management[47] Assets and Investments - The total assets at the end of 2017 increased by 104.03% to CNY 756,245,017.73 compared to the end of 2016[16] - The net assets attributable to shareholders rose by 156.39% to CNY 695,680,128.70 at the end of 2017[16] - The construction in progress increased from CNY 1,002,624.51 to CNY 4,925,803.91, a growth of 391.29%, mainly due to investments in the technology center and quality inspection building renovations[36] - Other current assets rose significantly from CNY 263,892.40 to CNY 328,721,567.91, a staggering increase of 124,519.33%, attributed to the use of idle funds for principal-protected financial products[36] - The total cash and cash equivalents increased by 625.36% to 56,216,882.25 CNY, reflecting improved liquidity[71] - The total investment cash inflow surged by 26,211.80% to 176,743,992.16 CNY, mainly due to the recovery of financial products[71] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 2.50 per 10 shares, totaling CNY 30,000,000 based on the total share capital[5] - The company distributed cash dividends of RMB 30,000,000, which is 34.91% of the net profit attributable to shareholders for the year 2017[104] - The cash dividend policy for 2017 was set at RMB 2.50 per 10 shares, based on a total share capital of 120,000,000 shares[105] - The company reported a total distributable profit of RMB 154,496,695.43 for the year 2017[105] - In 2016, the company distributed cash dividends totaling RMB 60,000,000, which accounted for 64.96% of the net profit attributable to shareholders[104] Business Operations and Market Position - The company has no changes in its main business since its listing[16] - The company’s primary business remains unchanged, focusing on the research, production, and sales of veterinary drugs and additives[26] - The company has established a wholly-owned subsidiary, Green Health (Pingtan) Investment Co., Ltd., to expand its business in the pharmaceutical and health sectors, with an investment of ¥46 million in a pharmaceutical industry fund[49] - The company is positioned to capitalize on the "Belt and Road" initiative, which is expected to enhance trade opportunities with numerous countries and regions[34] - The company’s products are exported to multiple countries, utilizing a combination of direct sales and distribution to mitigate risks and expand market reach[32] Research and Development - Research and development investment totaled 14,106,896.10 CNY, representing 3.76% of total revenue, an increase from 3.28% in 2016[67] - The company has established a technology center and collaborated with research institutions, enhancing its technological capabilities and innovation[39] - The company aims to develop new veterinary drug products that are "safe, efficient, low/no residue, and specific for livestock" to enhance product structure and market resilience[94] - The company is investing 100 million RMB in R&D for new technologies aimed at improving production efficiency and product quality[171] Regulatory and Compliance - The company adheres to GMP standards in production, ensuring high-quality manufacturing processes and dynamic inventory management to meet market demands[32] - The company has obtained new veterinary drug registration certificates for its Methane Salicylic Acid Bacillus Peptide products, enhancing its product portfolio and compliance with regulatory standards[27] - The company has received environmental impact assessment approval for its technology center expansion project from the local environmental protection bureau in May 2017[144] - The company’s emissions of chemical oxygen demand were reported at 19.59 tons per year, which is below the regulatory limit of 66.6 tons per year[143] - The company’s nitrogen oxides emissions were recorded at 61.74 tons per year, also below the regulatory limit of 258.65 tons per year[143] Shareholder Structure and Governance - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.32% of the shares, amounting to 36,378,000 shares, with 6,500,000 shares pledged[154] - The second largest shareholder, Helix (Asia) Investment Co., Ltd., holds 28.20% of the shares, totaling 33,840,000 shares[154] - The company has a total of 10 major shareholders, with the top 10 shareholders holding significant stakes, but the relationships among them are not fully disclosed[156] - The company has a total of 7 board members, including 3 independent directors, ensuring a diverse governance structure[168] - The company maintains independence from its controlling shareholder in business, personnel, assets, institutions, and finance[189] Risk Factors - The company faces risks related to changes in industry policies, environmental regulations, and currency fluctuations[97] - The company has a competitive risk in retaining and attracting talent due to the evolving industry landscape[97] Employee and Management Information - The total number of employees in the company is 501, with 476 in the parent company and 25 in major subsidiaries[182] - The professional composition includes 388 production personnel, 19 sales personnel, 53 technical personnel, 7 financial personnel, and 34 administrative personnel[183] - The company has established a skill-level salary system, linking employee performance bonuses directly to their job category and skill level[184] - The total remuneration for the company's directors and senior management during the reporting period amounted to CNY 4.7825 million[181] Future Outlook - The company has set a revenue guidance of 1.5 billion RMB for the next fiscal year, projecting a growth rate of 25%[171] - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on expanding the product line in the biopharmaceutical sector[171] - Market expansion plans include entering two new provinces, which are projected to increase market share by 10%[171]